1. Efficacy and safety of Liqingtong granules in the treatment of hyperuricemia: A randomized double-blind placebo-controlled pilot clinical trial
- Author
-
Jinlian Liu, Yi Yang, Meiyu Lv, Wenting Fei, Songrui Di, Mei Luo, Qing Lin, Chun Wang, Linyuan Wang, and Jianjun Zhang
- Subjects
Traditional Chinese medicine ,Hyperuricemia ,Liqingtong granules ,Dampness-heat pattern ,Clinical trial ,Miscellaneous systems and treatments ,RZ409.7-999 - Abstract
Objective: To investigate the efficacy and safety of Liqingtong (LQT) granules in patients with dampness-heat hyperuricemia. Methods: A randomized, double-blind, placebo-controlled pilot trial was conducted at the 983rd Hospital of the Joint Logistic Support Force of the People's Liberation Army from March 15, 2023, to August 10, 2023. In total, 119 participants were enrolled in this trial, and participants were given either LQT granules or placebo for 60 days based on a health education. The primary outcome was serum uric acid (SUA) level, and the secondary outcome was the traditional Chinese medicine (TCM) symptom score, measured on days 0, 30, and 60. Safety indicators, including liver function, kidney function, blood routine, glucose, blood lipid, blood pressure, and heart rate were tested on days 0 and 60 of the trial. The data were analyzed using Prism 9 software, and the significance level was set at P
- Published
- 2024
- Full Text
- View/download PDF